These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16318434)

  • 21. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
    J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
    Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
    Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
    Ristig MB; Crippin J; Aberg JA; Powderly WG; Lisker-Melman M; Kessels L; Tebas P
    J Infect Dis; 2002 Dec; 186(12):1844-7. PubMed ID: 12447773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir for the treatment of hepatitis B virus.
    Jenh AM; Thio CL; Pham PA
    Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
    van Bömmel F; Wünsche T; Mauss S; Reinke P; Bergk A; Schürmann D; Wiedenmann B; Berg T
    Hepatology; 2004 Dec; 40(6):1421-5. PubMed ID: 15565615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
    Sims KA; Woodland AM
    Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
    Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
    Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
    Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
    Nelson M; Portsmouth S; Stebbing J; Atkins M; Barr A; Matthews G; Pillay D; Fisher M; Bower M; Gazzard B
    AIDS; 2003 Jan; 17(1):F7-10. PubMed ID: 12478090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals.
    Johnson RM; Ristig MB; Overton ET; Lisker-Melman M; Cummings OW; Aberg JA
    HIV Clin Trials; 2007; 8(3):173-81. PubMed ID: 17621464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of hepatitis B virus co-infection on and off antiretroviral therapy.
    Soriano V; Vispo E; Bottecchia M; Sheldon J; Tuma P; Garcia-Samaniego J; Barreiro P
    Curr HIV/AIDS Rep; 2008 May; 5(2):86-93. PubMed ID: 18510894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
    Lada O; Gervais A; Branger M; Peytavin G; Roquebert B; Collin G; Fraqueiro G; Moucari R; Leclerc L; Martinot-Peignoux M; Matheron S; Marcellin P
    Antivir Ther; 2012; 17(1):61-70. PubMed ID: 22267470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients.
    Martin-Carbonero L; Soriano V
    J Antimicrob Chemother; 2010 Mar; 65(3):379-82. PubMed ID: 20085999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
    Treviño A; Soriano V; Madejon A; Rodriguez C; Barros C; Botecchia M; Tuma P; Del Romero J; de Mendoza C
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1273-6. PubMed ID: 20001517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of the Hepatitis B Virus/HIV-Coinfected Patient.
    Sherman KE
    Top Antivir Med; 2015; 23(3):111-4. PubMed ID: 26518394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for managing coinfection with hepatitis B virus and HIV.
    Sherman M
    Cleve Clin J Med; 2009 May; 76 Suppl 3():S30-3. PubMed ID: 19465707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
    Papatheodoridis GV; Dimou E; Papadimitropoulos V
    Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.
    Thio CL; Smeaton L; Hollabaugh K; Saulynas M; Hwang H; Saravanan S; Kulkarni S; Hakim J; Nyirenda M; Iqbal HS; Lalloo UG; Campbell TB; Lockman S; Currier JS
    AIDS; 2015 Jun; 29(10):1173-82. PubMed ID: 26035319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
    Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
    J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.